Antibodies and Corresponding Blocking Peptides
The use of antibodies and antibody-based technologies is now universally accepted in modern biomedical research laboratories. Any scientist working with antibodies has experienced the frustration of ambiguous results due reactive antibodies characterized by lack of specificity or low affinity. Issues related to poor results from Western blot (WB) analyses, immunoprecipitations (IP) or ELISA assays can potentially delay critical breakthroughs and have contributed to current initiatives demanding increased reproducibility in publications. To mitigate
these problems, MyBioSource carries thousands of high quality, well-characterized and species-specific antibodies from our worldwide network of manufacturers. We strive to select top selling products for our customers based on performance and PubMed citations (when available), and we routinely facilitate user flexibility by offering alternatives to the same antigen or epitope. We don't just market one specific antibody; we let the researcher choose the most appropriately matched product for their individual needs.
No good experiment or analysis is complete without appropriate controls. It is well established that antibodies are characterized by a tendency to react with homologous proteins and misleading results are occasionally problematic. To help our customers reduce the frequency of insufficiently validated results which can lead to publication rejections or revisions, MyBioSource has recognized the need for affordable negative controls, as an alternative to the costly options of knockout animals or si/shRNA knockdown cell experiments. Within the same easy to search database housing our extensive antibody collection we feature individual or antibody-paired blocking peptides. By combining a blocking peptide and antibody to the same epitope under defined conditions, the actual signal to noise ratios for proteins can often be determined.